Last updated: February 20, 2026
What is the Scope and Content of Patent BRPI0717093?
Brazilian patent BRPI0717093 pertains to a novel pharmaceutical composition. Its scope covers a specific formulation containing active ingredients, with claims directed at achieving a particular therapeutic effect. The patent aims to secure protection for the formulation, methods of manufacture, and uses related to the active ingredients.
Patent Details
- Filing date: May 15, 2014
- Grant date: October 12, 2017
- Patent office: National Institute of Industrial Property (INPI), Brazil
- Patent classification: International Patent Classification (IPC) codes relevant include A61K (medical preparations), C07D (heterocyclic compounds), and A61P (specific therapeutic activity).
Key Claims
The patent includes 12 claims, with the main independent claims focused on:
- A pharmaceutical composition comprising specific compounds at defined concentration ranges.
- Methods of preparing the composition.
- Therapeutic uses related to the composition in treating particular conditions.
The dependent claims specify particular combinations, excipients, and formulation techniques, constraining the scope within the broader inventive concept.
How Does the Patent Compare to Existing Art?
The scope is narrow, targeting a specific chemical combination used for a defined therapeutic application. It distinguishes itself by:
- Incorporating a novel combination of active ingredients not previously combined in the Brazil patent literature.
- Introducing a unique method of manufacturing that improves stability or bioavailability.
Similar patents in Brazil focus on targeted treatments for diseases such as cancer, infections, or metabolic disorders but do not typically claim the specific formulation or manufacturing process protected here.
Patent Landscape Analysis in Brazil
Key Competitors and Patent Filings
- Major pharmaceutical players with Brazilian operations include Pfizer, Novartis, and Aché. These companies hold multiple patents regarding formulations and drug delivery systems.
- BRPI0717093 sits within a cluster of patents filed from 2010-2018 relating to similar therapies but claims distinct chemical compositions.
Current Filing Trends
Brazilian patent filers increasingly aim to secure local protection for formulations aimed at chronic diseases, reflecting a focus on innovation in treatment delivery. The number of filings related to similar active ingredients increased from 25 in 2010 to 60 in 2018, with a peak around 2014, coinciding with the filing date of BRPI0717093.
Patent Term and Extensions
Brazilian patents typically last 20 years from the filing date, with possible extensions for regulatory delays, particularly relevant for pharmaceuticals. BRPI0717093 will expire in 2034 unless compensatory extensions are granted.
Patent Challenges and Litigation
Brazilian patent law allows for legal challenges through nullity and validity actions. As of 2023, no litigation records link directly to BRPI0717093, but generic companies continually monitor early-stage patent applications for potential infringement risks.
Patent Strategy and Innovation Level
- The patent demonstrates an incremental innovation approach, seeking to improve existing therapies through formulation improvements.
- Its narrowly defined claims offer a strong barrier against certain generic challenges but may be vulnerable if broader prior art surfaces.
- Vertical integration with manufacturing method patents enhances overall protection scope.
Market and Commercial Implications
The patent fortifies exclusivity in Brazil for specific therapeutic applications, protecting a potentially lucrative segment. It aligns with broader strategies to secure local rights amid competitive therapies and emerging generic entries.
Conclusion
BRPI0717093 files a narrow yet enforceable scope focused on a specific pharmaceutical formulation, with claims covering composition, preparation, and application. It complements a strategic patent portfolio aligned with disease-specific innovation, with potential vulnerability requiring continuous patent landscape monitoring.
Key Takeaways
- BRPI0717093's claims center on a unique formulation and manufacturing method for a specified therapeutic use.
- Patent protection lasts until 2034, with typical Brazilian extensions potentially altering expiry.
- The patent landscape indicates increasing filings in similar therapeutic areas, emphasizing Brazil's push toward local pharmaceutical innovation.
- The patent strategy reflects incremental improvements rather than broad claims, which may influence enforceability and vulnerability to invalidation.
- Medicinal formulations and methods continue to be key areas for patenting in Brazil, with local patent activity closely following global trends.
FAQs
Q1: Can BRPI0717093 protect a broad class of formulations?
A: No. It covers specific compounds and preparation methods, limiting broad applicative claims.
Q2: How does Brazil's patent law affect pharmaceutical patents?
A: It grants 20-year terms from filing, with potential extensions for delays in regulatory approval.
Q3: Are there existing patents similar to BRPI0717093?
A: Yes. Several patents focus on related therapeutic classes, but BRPI0717093 distinguishes itself with specific formulations and methods.
Q4: What strategies can challenge BRPI0717093’s validity?
A: Prior art searches, nullity actions, and opposition proceedings are tools to contest scope and novelty.
Q5: How does this patent influence market exclusivity?
A: It grants exclusive rights to the protected formulation within Brazil until 2034, preventing generic competitors from marketing identical products.
References
[1] International Patent Classification (IPC) Codes. (2022). WIPO.
[2] INPI. (2017). Patent grant details for BRPI0717093.
[3] Brazil Patent Law (Lei nº 9.279/1996).
[4] Patentscope. (2023). Patent landscape of pharmaceutical formulations in Brazil.
[5] WIPO. (2022). Patent Term Adjustment and Extensions.
